Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Income from Continuing Operations (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Income from Continuing Operations for 7 consecutive years, with 5534000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations rose 71.85% year-over-year to 5534000.0; the TTM value through Mar 2026 reached 52334000.0, up 19.88%, while the annual FY2025 figure was 66458000.0, 8.62% down from the prior year.
  • Income from Continuing Operations hit 5534000.0 in Q1 2026 for Barinthus Biotherapeutics, up from 11103000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15689000.0 in Q2 2022 and bottomed at 23824000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 11841235.29, with a median of 15520000.0 recorded in 2024.
  • Year-over-year, Income from Continuing Operations skyrocketed 248.69% in 2022 and then tumbled 807.96% in 2023.
  • Barinthus Biotherapeutics' Income from Continuing Operations stood at 21163000.0 in 2022, then rose by 18.3% to 17290000.0 in 2023, then dropped by 19.09% to 20591000.0 in 2024, then soared by 46.08% to 11103000.0 in 2025, then skyrocketed by 50.16% to 5534000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 5534000.0, 11103000.0, and 14571000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.